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Abstract 
Background: The initial treatment of acute necrotizing pancreatitis is conservative. Intervention is 
indicated in patients with (suspected) infected necrotizing pancreatitis. In the Netherlands, the standard 
intervention is necrosectomy by laparotomy followed by continuous postoperative lavage (CPL). In 
recent years several minimally invasive strategies have been introduced. So far, these strategies have 
never been compared in a randomised controlled trial. The PANTER study (PAncreatitis, 
Necrosectomy versus sTEp up appRoach) was conceived to yield the evidence needed for a considered 
policy decision. 
Methods/design: 88 patients with (suspected) infected necrotizing pancreatitis will be randomly 
allocated to either group A) minimally invasive ‘step-up approach’ starting with drainage followed, if 
necessary, by videoscopic assisted retroperitoneal debridement (VARD) or group B) maximal 
necrosectomy by laparotomy. Both procedures are followed by CPL. Patients will be recruited from 20 
hospitals, including all Dutch university medical centres, over a 3-year period. The primary endpoint 
is the proportion of patients suffering from postoperative major morbidity and mortality. Secondary 
endpoints are complications, new onset sepsis, length of hospital and intensive care stay, quality of life 
and total (direct and indirect) costs. To demonstrate that the ‘step-up approach’ can reduce the major 
morbidity and mortality rate from 45 to 16%, with 80% power at 5% alpha, a total sample size of 88 
patients was calculated. 
Discussion: The PANTER-study is a randomised controlled trial that will provide evidence on the 
merits of a minimally invasive ‘step-up approach’ in patients with (suspected) infected necrotizing 
pancreatitis. 
 
 
 
 
 
 
 
   
 
 4
Background  
The initial treatment of acute necrotizing pancreatitis is conservative[1-4]. Once (peri-)pancreatic 
necrosis becomes infected mortality increases steeply[3,4]. Intervention is indicated when infection of 
(peri-)pancreatic necrosis is proven by fine needle aspiration (FNA), when (peri-)pancreatic air 
collections in the necrotic cavity are depicted on computer tomography (CT) scan or when sepsis 
persists despite maximal support on the intensive care unit. Surgical intervention within the first 14 
days after the onset of symptoms should be averted because of notoriously poor outcome in this phase 
of disease[4,5]. Organ failure needing intensive care treatment during the first two weeks should be 
interpreted as a complication of a systemic inflammatory response syndrome (SIRS). 
 
There is no consensus in the literature on the optimal surgical strategy in infected necrotizing 
pancreatitis. In a recent systematic review we demonstrated that necrosectomy by laparotomy was 
accompanied by high mortality rates (15-27%) and considerable morbidity[6]. 
 
In recent years radiologists, gastrointestinal surgeons and gastroenterologists have adopted minimally 
invasive strategies in infected necrotizing pancreatitis[7]. Initially only practiced in patients unfit for 
laparotomy, but in recent years indications seem to have expanded[8-11]. Percutaneous catheter 
drainage (PCD)[12-14], endoscopic transgastric procedures[15,16] and minimally invasive 
necrosectomy[9-11] have been proposed as alternatives for necrosectomy by laparotomy. Although 
preliminary results are promising, current series are small, poorly comparable and a selection bias may 
have influenced the results[7].  
 
It has been reported that PCD obviates the need for surgical intervention in infected necrotizing 
pancreatitis in 30 to 100 per cent of cases[12-14]. In these series committed radiologists repeatedly 
performed repeated drainage procedures using large bore catheters. It has been argued that because of 
the need for repeated procedures PCD can not easily be implemented in clinical practice[17]. 
However, we hypothesize that ‘simple’ drainage with regular bore (12-14 French) percutaneous 
catheters can also be beneficial to the patient. Drainage of ‘infected fluid under pressure’ may help the 
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patient in dealing with the (peri-)pancreatic necrosis and delay or even obviate surgical intervention in 
a relevant proportion of patients.  
 
As a prelude to the present study a retrospective multicenter study was performed in 11 hospitals in 
the Netherlands[8]. The outcome of the different interventional strategies in (infected) necrotizing 
pancreatitis was assessed. The strategy most often used was laparotomy with continuous postoperative 
lavage (CPL) (53/106 patients)[8]. Of the patients treated with minimally invasive surgery (n=18), 
two-thirds had PCD prior to surgical intervention. During surgery the percutaneous drain was used as 
a ‘guide wire’ to facilitate retroperitoneal access to the infected collections. The results of minimally 
invasive surgery were favourable: 11% mortality as compared to 25% after laparotomy and CPL. 
However, since selection bias may have played a role in the favourable results a randomised controlled 
trial is warranted in order to define evidence-based surgery in infected necrotizing pancreatitis.  
 
We anticipate that a minimally invasive ‘step-up approach’ results in a reduction in postoperative 
major morbidity and mortality. The PANTER trial is designed to compare a minimally invasive ‘step-
up approach’ with a  primary maximal necrosectomy by laparotomy. The ‘step-up approach’ consists 
of percutaneous or transgastric drainage when necessary followed by minimally invasive 
necrosectomy. 
 
 
 
 
 
 
 
   
 
 6
Methods / design 
Study objectives 
To test the hypothesis that a minimally invasive ‘step-up approach’ will lead to a reduction of 
postoperative major morbidity and mortality in patients with infected (peri-)pancreatic necrosis.  
 
Primary endpoint 
The primary endpoint is the proportion of patients with major morbidity or mortality, see Tables 1 and 
2. Complications occurring subsequent to the first intervention after randomisation until three months 
after discharge from the hospital are compared.  
 
Secondary endpoints 
Secondary endpoints are ‘minor’ complications (such as pancreatic fistula, pancreatic pseudocyst 
requiring intervention, pancreatic abscess, biliary strictures, incisional hernia requiring re-intervention 
and pancreatic insufficiency), new onset sepsis, new onset SIRS, total number of interventions, 
hospital and intensive care stay, quality of life and total (direct and indirect) costs.  
 
Definitions 
The definitions of the Atlanta classification are used. Pancreatic necrosis: focal area’s of non-
enhancing pancreatic parenchyma on contrast-enhanced computer tomography (CECT). Infected 
necrotizing pancreatitis: a positive culture of pancreatic or peripancreatic necrosis obtained by FNA 
or the presence of air in the collections on CECT. Suspected infected necrotizing pancreatitis: 
persisting sepsis or progressive clinical deterioration despite maximal support on the intensive care 
unit in case of pancreatic and/or peripancreatic necrosis. 
 
Design of Study 
PANTER is a randomised controlled parallel group superiority multicenter trial.  
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Participating centres 
Twenty hospitals of the Dutch Acute Pancreatitis Study Group, including all Dutch University 
Medical Centres, will enrol patients (see Appendix). 
 
Pre-randomisation treatment protocol 
All patients with acute pancreatitis will be treated by a pre-established treatment protocol consisting of 
enteral nutrition via a nasojejunal tube and an early endoscopic retrograde cholangiopancreatography 
(ERCP) with sphincterotomy in case of predicted severe biliary pancreatitis with or without 
obstructive cholangitis. No antibiotic prophylaxis will be administered. CECT will be performed in 
patients who fail to show clinical improvement after the first 7 days of hospital admission. Since many 
patients are referred from other centres, violation of the pre-randomisation treatment protocol is not an 
exclusion criteria. 
 
Registration 
From all patients with (peri-)pancreatic necrosis, including those who are not randomised and treated 
conservatively, written  informed consent will be obtained for prospective registration of age, gender, 
onset of symptoms, interventional procedures, hospital stay, intensive care stay and mortality 
(alternatively consent by proxy will be obtained for patients who are unable to give consent eg. 
intubated patients). 
 
Timing of intervention  
Whenever possible it is attempted to delay surgical intervention. Ideally, the first intervention would 
be performed at least 30 days after onset of symptoms. Earlier intervention may be warranted in case 
of a rapidly deteriorating clinical condition. When infection is proven within the first 14 days, 
intervention may be postponed. Intervention within 14 days is only indicated in emergencies such as 
bowel perforation, abdominal compartment syndrome or acute bleeding. Patients with these 
complications are not eligible for randomisation.  
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Eligibility criteria 
Inclusion criteria 
 age equal to or above 18 years 
 pancreatic necrosis or peripancreatic necrosis detected on CECT. 
 patients in whom a decision for surgical intervention has been made because of (suspected) 
infected (peri-)pancreatic necrosis  
 possibility of placing a drain (either percutaneous or endoscopic) in the collection(s) 
 written informed consent 
 
Exclusion criteria 
 previous drainage or surgical necrosectomy for (suspected) infected pancreatic necrosis, including 
procedures performed in referring hospitals. ERCP with or without papillotomy is allowed. 
 previous exploratory laparotomy for acute abdomen and diagnosis of pancreatitis during 
laparotomy 
 acute flare-up of chronic pancreatitis 
 bleeding, abdominal compartment syndrome or perforation of a visceral organ as indication for 
intervention 
 post-abdominal surgery necrotizing pancreatitis 
 
Rationale: previous drainage procedures or laparotomy make it impossible to study the isolated effect 
of drainage of ‘infected fluid under pressure’. There is essentially no indication for necrosectomy in 
acute fluid collections, pancreatic abscesses or pseudocysts as these collections do not contain 
pancreatic necrosis or necrotic debris according to the Atlanta Classification. When intervention is 
indicated in these types of collections this is performed by drainage procedures, although some 
pseudocysts may require surgical intervention[4]. Patients with chronic pancreatitis have an 
underlying disease with a course very different from acute pancreatitis. Patients with a second, third or 
fourth attack of acute pancreatitis are eligible for randomisation as long as there are no signs of 
chronic pancreatitis (calcification and/or pancreatic duct abnormalities).  
  
Randomisation 
Patients will be randomly assigned to group A (‘step-up approach’) or group B (laparotomy) as shown 
in the flowchart (see figure 1). Randomisation is performed by an Internet randomisation module 
(Julius Center for primary care and health sciences, UMC Utrecht, the Netherlands). Block-
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randomisation is used and the randomisation is stratified according to the (im-)possibility of placing a 
percutaneous drain through the (preferably left) retroperitoneum, since this step is essential to perform 
minimally invasive necrosectomy. 
 
Ethics 
This study is conducted in accordance with the principles of the Declaration of Helsinki and ‘good 
clinical practice’ guidelines. The independent medical ethics committees of all 20 participating 
hospitals have approved the study protocol. Prior to randomisation, written informed consent will be 
obtained from all patients (alternatively consent by proxy will be obtained for patients who are unable 
to give consent, e.g., intubated patients). 
 
Safety and quality control 
The indication and timing of intervention in necrotizing pancreatitis can be difficult. Therefore, prior 
to randomisation using CECT images and a ‘summarized case report’ an expert panel consisting of 
three surgeons (MAB, HSH, HGG), a gastroenterologist (RT) and three radiologists (TLB, MSVL, 
HSL) will assess the indication and feasibility of surgical, gastroenterological or radiological 
intervention. All procedures will be performed by experienced radiologists, gastroenterologists or 
gastrointestinal surgeons. All endo-/videoscopic procedures will be videotaped. In case of a planned 
intervention, surgeons or radiologists from (neighbouring) participating hospitals and the trial 
coordinator will join the procedure in order to increase experience and enhance protocol-compliance. 
Every four months a study group meeting will be organised in which the CECT images and the 
‘summarized case report’ of all newly randomised patients will be discussed. An independent 
monitoring-committee, consisting of two surgeons, a gastroenterologist, an epidemiologist and a 
radiologist, will discuss (serious) adverse events and give advice to the trial steering committee.  
 
Statistical analysis 
Intention- to-treat 
The analysis will be performed in accordance with intention-to-treat (ITT) principle  
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Sample size and sequential interim-analysis 
Sequential analysis is used to determine the difference in treatment effect on the primary endpoint (see 
Methods/design section), therefore no fixed sample size estimate can be given[18]. Based on the 
results of the Dutch retrospective multicentre audit (mortality 25% versus 11%) and PCD results from 
the literature is anticipated that the minimally invasive ‘step-up approach’ will reduce the occurrence 
of the primary endpoint from 45% to 16%. The expected reduction of mortality and morbidity are 10% 
and 19% respectively. With 80% power at 5% alpha (two-sided) complete data from about 52-77 
patients will be necessary to demonstrate this effect, if it truly exists. If no such effect appears, the trial 
will continue until 88 patients are randomised and available for analysis as ‘conventional’ sample size 
calculation with 80% power at 5% alpha (two-sided) would require 88 patients. 
Descriptive methods will be used to assess the quality of the data, comparability of treatment groups 
and endpoints. Continuous sequential analysis will be performed with PEST (PEST 4: user manual. 
MPS Research Unit (2000), the University of Reading) according to the restricted procedure as 
described by Whitehead[18]. Every time an endpoint occurs, data management will send a blinded, 
updated dataset of all included patients to the biostatistician. If one of the boundaries of the sequential 
analysis plot is crossed during the analysis of the cumulative data, i.e. the difference in treatment is of 
at least the expected magnitude, the trial steering committee will be informed and will be advised to 
stop randomising new patients for the trial. The trial steering committee will not be advised to stop 
early when no relevant differences between the treatments are observed.  Next to the primary analysis, 
the outcome of both groups will also be adjusted for imbalance in presence of preoperative (multi-) 
organ failure and timing of intervention (after 28 days). These factors, including possibility of 
performing VARD and the individual components of the primary endpoint will also be included in a 
multivariate and subgroup analysis. 
 
Feasibility 
The recent retrospective survey showed that in a 3-year period 106 patients had undergone surgery for 
necrotizing pancreatitis in 11 of the 20 participating Dutch hospitals[8]. It is expected that up to 25% 
   
 
 11
of eligible patients will be excluded mainly because of interventions (percutaneous drainage or 
surgery) being performed prior to randomisation in referring centres. Taking further into account 
refusal of informed consent (10%), other reasons for drop-out (5%) and loss-to-follow-up (2.5%) it is 
considered possible to randomise and collect data on 88 patients in 3 years time. After one year, the 
inclusion rate will be assessed. If accrual is too slow, additional centres will be invited to participate.  
 
Post-randomisation treatment protocol 
All patients receive oral nutrition. If this is not tolerated, a nasojejunal feeding tube is introduced and 
enteral feeding is started[19]. If gastrointestinal feeding is contra-indicated, the patient will receive 
parenteral nutrition. Antibiotic treatment, Imipenem-cilastatin therapy 500 mg 3 times daily, is started 
in all patients with a maximum duration of fourteen days. Antibiotic treatment is switched based on 
blood cultures and culture from material collected during drainage and/or surgical procedures. If 
cultures remain negative antibiotic treatment is stopped. Selective decontamination of the digestive 
tract is allowed.  
 
Group A: minimally invasive ‘step-up approach’ 
Step 1: Drainage  
A percutaneous drain (at least 12 French) is placed in the (peri-)pancreatic collection. Multiple drains 
may be indicated in case of large or multiple collections. The preferred route is through the left 
retroperitoneum. If this is not possible a transperitoneal route is chosen. A right retroperitoneal route is 
allowed when it can be safely applied. If this is also not possible, an endoscopic transgastric drainage 
is performed with two 10 French drains (10 French being the current maximal drain size for 
endoscopic procedures) including a nasocystic drain for flushing. No continuous lavage system is 
installed. Drains are kept open by flushing with 50 ml saline once every 8-hrs shift by nursing staff. 
Extra saline may be used depending on the aspect of the return-fluid, the size of the collections on 
CECT, communication between drains and connections between collections. If more than 200 ml 
saline is used daily a drain fluid-balance chart is kept.  
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If there is no clinical improvement 72 hours after drain placement, this is considered a failure and a 
CECT is made to check the position of the drain. “Clinical improvement” is defined as: improved 
function of at least two organ systems (circulatory, pulmonary, renal) within 72 hours, or at least 10% 
improvement of two out of three parameters: leucocytes/ temperature/ CRP. If during the repeat CECT 
the position of the drain is adequate and no additional drainable collections are seen, the patient is 
taken to the operating room (step two). If the position of the drain is inadequate a second drain is 
placed in the collection.  
Seventy-two hours after a second drainage-procedure the patient is again evaluated. In case of 
improvement, treatment is conservative; otherwise the patient will be taken to the operating room (step 
two). If after drainage, at any moment in time, a deterioration of at least two organ systems 
(circulatory, pulmonary, renal), or at least 10% deterioration of two out of three parameters: 
leucocytes/ temperature/ CRP occurs, step two is taken. Deterioration (of these parameters) by other 
infectious causes (e.g. an urinary tract infection) should be excluded. 
 
Step two: Videoscopic assisted retroperitoneal debridement  
The percutaneous retroperitoneal drain is used for videoscopic assisted retroperitoneal debridement 
(VARD). VARD has been used in several of the participating centres since 2000. The technique was 
recently described by Horvath et al[11]. See figure 2.  
1. The patient is placed in a supine position with the left side elevated. 
2. The left flank and the entire abdomen are prepared and draped. 
3. Based on the position of the drain a 5 cm sub- or intercostal incision is made in the left flank.  
4. With digital exploration the retroperitoneal drain is followed into the collection.  
5. The collection is opened and necrosectomy performed with ring forceps and suction device.  
6. A long 10mm trocar and a 10 mm long zero degree videoscope (laparoscope) are inserted through 
the incision in the retroperitoneum.  
7. With the videoscope the cavity is inspected and remaining, loosely adherent, necrosis is removed 
with a laparoscopic grasper or ring forceps. Note: it is not considered mandatory to remove all 
necrotic material.  
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8. Two large bore surgical drains are placed in the collection via the incision and the skin is closed 
between the drains. 
If VARD is technically not feasible, laparotomy by bilateral subcostal incisions is performed as in 
Group B. Outcome of these patients will be analysed in group A according to the intention-to-treat 
principles.  
 
Group B: maximal necrosectomy by laparotomy 
Laparotomy is performed with a bilateral subcostal incision. The lesser sac is entered through the 
omentum and carefully inspected. Blunt debridement of all necrotic tissue is performed. Two large 
bore drainage tubes are inserted through separate incisions with their tips in the lesser sac and necrotic 
cavities, the entrance to the lesser sac is carefully closed to create a contained space for CPL[20]. In 
case of diffuse bleeding, it is advisable to perform packing with gauzes that are to be removed the next 
day. Consequently, the lavage system is then installed on the first postoperative day.  
 
Both in group A and in group B, necrotic material is collected during necrosectomy for culture and the 
total amount of necrotic tissue collected is weighed and photographed.  
 
Postoperative management 
The postoperative management is similar in both groups. Continuous postoperative lavage with 
normal saline or peritoneal dialysis (CAPD) fluid is started. On the third postoperative day, the lavage 
should amount to at least 10 litres per 24 hours. CECT is performed one week after every drain 
placement and surgical intervention. Catheters are removed if collapse of the cavity is shown on 
CECT with contrast through the drainage system (or: on a sinogram of the cavity), and daily 
production of clear fluids has decreased below 50 ml / 24 hours. Patients can be discharged with 
catheters in place and continue irrigation at home. Time to final removal of the drains will be recorded. 
 
Indication for re-intervention 
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Re-intervention is performed ‘on-demand’. Planned re-intervention is only performed in case ‘packing 
materials’ have been left in-situ during the first procedure. A re-intervention for removal of necrotic 
remnants is, whenever technically feasible, performed in accordance with the strategy the patient was 
initially assigned to. However, a pancreatic abscess (a collection consisting only of pus without 
necrosis) is treated by percutaneous drainage only. 
 
Data collection 
Data are collected via a secured Internet module which was specifically designed for the PANTER 
trial (Julius Center for primary care and health sciences, UMC Utrecht, the Netherlands). Data are 
entered online but are not stored on the Internet. Sequential Organ Dysfunction Scores (SOFA) are 
noted at randomisation[21,22]. The SOFA score, major morbidity (Table 1) and other complications 
are registered every second day for the first month and twice weekly thereafter until discharge. 
Furthermore at any (re-)intervention the SOFA score, procedure-related data (length of procedure, 
blood-loss) and procedure-related complications are scored. 
 
Data monitoring 
There will be regular contact (by telephone, e-mail and site-visits) between the study coordinators and 
participating centres. Two study nurses will monitor the entered data. Twice a year a minimum of 10% 
of the data, including all end points, will be verified (double-checked) with source data at the study 
site by an independent monitor. 
 
Follow-up 
Patients are observed during their hospital stay. Follow-up visits are planned after 3 and 6 months. For 
the primary endpoint, follow-up is completed at 3 months and for the secondary endpoints at 6 months 
after discharge, with a physical examination to exclude incisional hernia and ultrasonography to 
exclude a pancreatic pseudocyst.  
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Discussion 
A recent Dutch retrospective multicenter study showed that laparotomy with CPL is the current 
standard for treatment of infected necrotizing pancreatitis as it is the technique most frequently used in 
the Netherlands with consistently and relatively good results[8]. In this series, mortality for the ‘open-
abdomen-strategy’ was 70% (intention-to-treat analysis) which is unacceptably high. The 
‘experimental arm’ in PANTER is a minimally invasive ‘step-up approach’. Notably, in necrotizing 
pancreatitis a minimally invasive approach does not only aim at minimising surgical stress, it is also 
part of a different treatment concept. We hypothesize that it is not necessary to remove all necrotic 
tissue in order to successfully treat patients with infected necrotizing pancreatitis. By performing 
drainage of ‘infected fluid under pressure’ the clinical condition may improve and the necrotic tissue 
may successfully be dealt with by the patient’s immune system. It is therefore not the goal of drainage 
to remove (peri-)pancreatic necrosis but merely the infected fluid.  
 
The second step of the minimally invasive ‘step-up approach’, ‘VARD’, is only performed if the first 
step fails. VARD combines endoscopic ‘drain-tract’ necrosectomy as first described by Carter et al[9]. 
and an open retroperitoneal approach. In our opinion VARD has the advantage of endoscopic 
necrosectomy as it is minimally invasive. However, VARD lacks the disadvantages of being 
technically demanding and time consuming. In VARD the relatively small 5 cm incision greatly 
facilitates the ‘debulking’ part. This will not only reduce the operating time but also potentially reduce 
the number of procedures needed to remove the necrotic tissue. 
 
It has been argued that minimally invasive procedures are only feasible in a small subgroup of 
necrotizing pancreatitis patients. Our group recently performed a feasibility study re-evaluating CT 
scans of 80 patients operated upon for (suspected) infected necrotizing pancreatitis and found that in 
the vast majority of patients PCD is technically feasible and that in the majority of patients VARD is 
possible[23].  
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Currently, there are no randomised controlled trials comparing surgical techniques in necrotizing 
pancreatitis most likely due to low patient volumes, the heterogeneity of the disease and the highly 
individualized approach. The Dutch Acute Pancreatitis Study Group was founded to resolve several of 
these problems[24]. Since 2004, 15 of the 20 centres participating in PANTER are also participating in 
PROPATRIA, a placebo-controlled trial of probiotic prophylaxis in predicted severe acute 
pancreatitis[25]. Patients who initially are included in PROPATRIA are screened for eligibility in 
PANTER. Once a patient develops infected necrotizing pancreatitis the outcome for PROPATRIA is 
reached and he/she can be randomised for PANTER. With this already ongoing multicenter 
cooperation the logistical and organisational problems are expected to be kept at a minimum.  
 
The sequential analysis of the primary outcome enables us to stop the trial as soon as sufficient 
evidence has accumulated regarding both clinically relevant and statistically significant treatment 
difference. Compared to a conventional fixed sample size sequential analysis on average requires less 
patients to show an expected effect if it truly exists[18]. This can be advantageous when the disorder is 
as rare as infected necrotizing pancreatitis. Moreover, as soon as the predefined threshold is passed 
randomisation may seize, thus preventing further patients to be subjected to an inferior treatment. If 
the presumed effect does not exist, based on conventional sample size calculations, 88 patients will be 
randomised. 
 
A possible disadvantage of the present study concept is the large number of centres participating. In 
the Netherlands centralisation has not reached a level that all patients are referred to tertiary 
centres[8,26]. However, the 20 hospitals participating are amongst the largest of the 101 Dutch 
hospitals and all have experienced gastrointestinal surgeons, gastroenterologists and radiologists, 
including for example interventional radiology facilities to treat imminent bleeding. Furthermore, 
since in the Netherlands distances between any participating hospital and the nearest university 
medical centre is always within 10-100 kilometres, referral of patients is generally accepted and easy. 
A second possible disadvantage is the exclusion criteria ‘previous placement of percutaneous drains’. 
This may apply to a considerable number of patients. The steering committee will repeatedly address 
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this issue in meetings with referring physicians. Finally, in a trial with a rare disease such as infected 
necrotizing pancreatitis accrual is expected to be difficult. If after the first year less than 85% of the 
expected patients are recruited the study group will invite (inter-)national centres to join PANTER. 
 
Conclusion 
PANTER is a randomised controlled multicenter trial set out to reveal a reduction in major morbidity 
by introducing a minimally invasive ‘step-up approach’ instead of maximal necrosectomy by 
laparotomy in patients with (suspected) infected necrotizing pancreatitis. Results are expected by 
2008. 
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Figure legends  
Figure 1. PANTER according to CONSORT 
 
Figure 2. PANTER flowchart 
® = randomisation 
 
 
#In the intensive care: within 72 hours, improved function of at least two organ systems (renal/ 
respiratory/ cardiovascular) or in the ward: within 72 hours, improvement of two of these three 
parameters: leucocytes/ temperature/ CRP). The worst parameter is used. 
 
§No clinical improvement within 72 hours after drainage is considered failure: repeat the CT-scan once 
to check position of the drains. If the position is adequate, and no additional drainable collections are 
seen, proceed to surgery, if drain position is inadequate: repeat CT-guided percutaneous drainage (or 
endoscopic transgastric drainage). If after the second drainage there is no clinical improvement within 
72 hours, proceed to surgery. If repeat-drainage is not possible, patients proceed to surgery. 
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Table 1: Primary outcome of the PANTER trial; complications after first intervention 
Mortality  
New-onset multi organ failure or systemic complications # 
Enteric fistula (either small or large bowel) 
Perforation of a visceral organ requiring intervention 
Bleeding requiring intervention* 
#
 New onset failure of 2 or more organ systems or systemic complications  
as listed in Table 2, occurring at  the same moment in time.  
*Surgical, endoscopic or radiological 
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Table 2: Definitions of organ failure and systemic complications 
CIRCULATORY SYSTOLIC BLOOD PRESSURE LESS THAN 90 MM HG 
OR NEED FOR CATECHOLAMINE SUPPORT 
Pulmonary PaO2 60mm Hg or less or need for mechanical 
ventilation 
ORGAN 
FAILURE 
Renal creatinine level greater than 177 umol/L after rehydration or 
or need for hemofiltration or hemodialysis 
Gastrointestinal bleeding more than 500 ml/ 24 hours 
Disseminated intravascular coagulation platelets <100 x 109/L  
Systemic 
complications 
Severe metabolic disturbance calcium level <1.87 mmol/L  
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
To be assessed for 
eligibility (n=151) 
To be randomised 
(n=90)* 
Not meeting randomisation  
criteria (n=38)  
Refusal to participate (n=15) 
Other reasons (n=8) 
Allocated to a ‘step-up approach’ (n=45)  
 
Complete data (n=44) Complete data (n=44) 
Lost to follow up (n=1) 
Allocated to laparotomy (n=45)  
 
Lost to follow up (n=1) 
Figure 1
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
® 
Group A 
Minimally invasive ‘step up approach’ 
Group B 
Maximal necrosectomy 
Videoscopic Assisted Retroperiteoneal Debridement (VARD) 
If VARD is not possible, laparotomy similar to group B is performed.  
In both cases CPL >4L/24 hrs is installed 
 
In case of clinical improvement# wait and see  
If no clinical improvement or deterioration, repeat CT-scan once§ 
 
 
 
 
Laparotomy, maximal 
necrosectomy  
and continuous  
postoperative lavage 
(CPL) >4L/24hrs 
Drain placement 
1. Percutaneous through left retroperitoneum (preferred strategy) 
2. Percutaneous transabdominal  
3. Endoscopic transgastric  
 
Check in- and exclusion criteria  
CT-scan: drain placement possible? 
 
Figure 2
